特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インスリン様成長因子2:パイプライン製品の分析

Insulin Like Growth Factor II - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 364848
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
インスリン様成長因子2:パイプライン製品の分析 Insulin Like Growth Factor II - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 48 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、インスリン様成長因子2を標的とした治療薬の開発に関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

インスリン様成長因子2の概要

治療薬の開発

インスリン様成長因子2:開発中の製品 - 開発段階別

インスリン様成長因子2:開発中の製品 - 治療範囲別

インスリン様成長因子2:開発中の製品 - 適応症別

インスリン様成長因子2:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

インスリン様成長因子2:企業で開発中の製品

インスリン様成長因子2:大学/機関で開発中の製品

インスリン様成長因子2:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

インスリン様成長因子2の治療薬開発に従事している企業

  • Boehringer Ingelheim GmbH
  • MedImmune, LLC

薬剤プロファイル

インスリン様成長因子2:休止中のプロジェクト

インスリン様成長因子2:主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Pipeline by Genervon Biopharmaceuticals LLC, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2435TDB

Summary:

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 7 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor II - Pipeline Review, H1 2020, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Insulin-like growth factor 2 (IGF-2) is a protein hormone. IGF-2 is influenced by placental lactogen and plays a role in fetal development. It undergoes glucose-mediated co-secretion with insulin and acts as physiological amplifier of glucose-mediated insulin secretion. It exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.

The molecules developed by companies in Phase II stages are 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Acute Ischemic Stroke, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Huntington Disease, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Parkinson's Disease and Solid Tumor.

Furthermore, this report also reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
  • The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Overview
    • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Companies Involved in Therapeutics Development
    • Boehringer Ingelheim International GmbH
    • Genervon Biopharmaceuticals LLC
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drug Profiles
    • GM-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-610.27 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-630 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Inhibit IGF-2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IGF-2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • xentuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Dormant Products
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Discontinued Products
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer